Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses,Arthritis & Rheumatology

当前位置： X-MOL 学术 › Arthritis Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses
Arthritis & Rheumatology ( IF 11.4 ) Pub Date : 2024-05-21 , DOI: 10.1002/art.42921
Oliver FitzGerald ₁ , Dafna D Gladman ₂ , Philip J Mease ₃ , Christopher Ritchlin ₄ , Josef S Smolen ₅ , Lu Gao ₆ , Yanhua Hu ₆ , Miroslawa Nowak ₆ , Subhashis Banerjee ₆ , Ian Catlett ₆

Affiliation

Our objective was to evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib.

中文翻译：

Deucravacitinib 治疗银屑病关节炎的 2 期试验：与疾病活动性、药效学和临床反应相关的生物标志物

我们的目的是评估血清生物标志物与基线银屑病关节炎 (PsA) 疾病活动的关联、deucravacitinib 对生物标志物水平的药效学影响，以及生物标志物与 deucravacitinib 临床反应之间的关系。

更新日期：2024-05-21

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南